# A Trial of CRD-4730 in HFrEF

> **NCT07750873** · PHASE2 · RECRUITING · sponsor: **Cardurion Pharmaceuticals, Inc.** · enrollment: 525 (estimated)

## Conditions studied

- Heart Failure With Reduced Ejection Fraction (HFrEF)

## Interventions

- **DRUG:** CRD-4730
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07750873
- **Lead sponsor:** Cardurion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-15
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 525 (ESTIMATED)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07750873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07750873, "A Trial of CRD-4730 in HFrEF". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07750873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*